Q-omics provides the consensus-scored CNOT9 profile across patient tissues and cancer cell-line models. CNOT9 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CNOT9 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, CNOT9 protein abundance shows 23,463 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where CNOT9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNOT9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNOT9 survival associations across molecular data types. CNOT9 RNA expression shows survival associations in the most cancer types (29), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNOT9 RNA expression–survival associations across cancer types. High CNOT9 expression shows unfavorable associations in ACC, KIRP, LIHC, MESO and UVM, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CNOT9 RNA expression.
This table summarizes CNOT9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CNOT9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNOT9 shows higher tumor expression in KIRC, COAD, HNSC, BLCA, LUAD and LIHC. The KIRC box plot shows higher CNOT9 RNA expression in tumor versus normal tissue (log2 FC = +0.688, t-test p < 0.001).
This table shows molecular features associated with CNOT9 in patient tissues and cancer cell lines. In patient samples, CNOT9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CNOT9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
